• Publications
  • Influence
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors.
GTI-2040 appears to have a manageable toxicity profile and is generally well tolerated as a single agent in patients with advanced solid tumors or lymphoma. Expand
GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors.
The results of these studies indicate that GTI-2040 can act as a selective and specific anticancer agent against a broad range of human tumors. Expand
Optimization of the PAXgene™ blood RNA extraction system for gene expression analysis of clinical samples
The results suggest that RNA isolation with PAXgene™ is advantageous compared to traditional extraction methods for RT‐PCR analysis of large or different‐sized amplicons, and off‐column DNase treatments, which yielded high‐quality RNA suitable for gene expression studies. Expand
IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo
It is demonstrated that B cells are necessary for IL-17E-mediated antitumor activity and that IL-13E was found to activate signaling pathways in B cells in vitro, and support further investigation of the potential clinical use of IL- 17E as an anticancer agent. Expand
Glucocorticoids increase protein carbonylation and mitochondrial dysfunction.
The results suggest that excessive glucocorticoid activity can increase oxidative damage to protein, possibly by inhibiting activities of mitochondrial complex I and antioxidant enzyme SOD. Expand
Liposome formulation of a novel hydrophobic aryl-imidazole compound for anti-cancer therapy
The in vivo evaluation of the anti-cancer activity in a human colon HT29 carcinoma model revealed a significant delay in tumor growth, highlighting the potential of cholesterol-free liposomes as a formulation strategy for highly lipophilic drugs. Expand
Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma.
  • M. Cao, Y. Lee, +7 authors A. Young
  • Medicine, Biology
  • Clinical cancer research : an official journal of…
  • 1 October 2003
Ribonucleotide reductase is the enzyme responsible for the reduction of ribonucleotides to their corresponding deoxyribonucleotides for DNA synthesis. Ribonucleotide reductase is a multisubunitExpand
Potent antimicrobial activity of 3-(4,5-diaryl-1H-imidazol-2-yl)-1H-indole derivatives against methicillin-resistant Staphylococcus aureus.
A new series of antimicrobial derivatives have been synthesized with potent activity against strains of Staphylococcus aureus, including methicillin-resistant strains (MRSA), and the most active derivative was shown to inhibit the growth of all Gram-positive strains tested. Expand
RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo
In vitro studies demonstrate sequence-specific down-regulation of R2, which coincides with a decrease in cell proliferation, and cell cycle inhibition, and indicate that treatment with short interfering siRNA 1284 leads to inhibition of tumor growth and this effect was found to be dose dependent. Expand
Virulizin, a novel immunotherapy agent, stimulates TNFalpha expression in monocytes/macrophages in vitro and in vivo.
  • H. Li, M. Cao, +11 authors A. Young
  • Biology, Medicine
  • International immunopharmacology
  • 1 October 2007
The results indicate that Virulizin-induced TNFalpha expression contributes to modulation of immune responses and antitumor activities. Expand